Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.

about

Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.

Item

http://www.wikidata.org/entity/Q50067311

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Rectal Gastrointestinal Stroma ...... nd Improved Oncologic Outcome.

@en

Rectal Gastrointestinal Stromal Tumor

@nl

type

Item

label

Rectal Gastrointestinal Stroma ...... nd Improved Oncologic Outcome.

@en

Rectal Gastrointestinal Stromal Tumor

@nl

prefLabel

Rectal Gastrointestinal Stroma ...... nd Improved Oncologic Outcome.

@en

Rectal Gastrointestinal Stromal Tumor

@nl

P1476

Rectal Gastrointestinal Stroma ...... nd Improved Oncologic Outcome.

@en

P2093

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

Garrett M Nash

http://www.w3.org/2001/XMLSchema#string

Jose G Guillem

http://www.w3.org/2001/XMLSchema#string

Julio Garcia Aguilar

http://www.w3.org/2001/XMLSchema#string

Larissa Temple

http://www.w3.org/2001/XMLSchema#string

Lin Wang

http://www.w3.org/2001/XMLSchema#string

Martin R Weiser

http://www.w3.org/2001/XMLSchema#string

Mary Keohan

http://www.w3.org/2001/XMLSchema#string

Michael J Cavnar

http://www.w3.org/2001/XMLSchema#string

Philip B Paty

http://www.w3.org/2001/XMLSchema#string

P2860

Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study.

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group.

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.

P2888

s10434-017-6087-9

P304

3972-3980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-017-6087-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092335273

http://www.w3.org/2001/XMLSchema#string

P698

29058144

http://www.w3.org/2001/XMLSchema#string

P932

5720861

http://www.w3.org/2001/XMLSchema#string